
Ninlaro
My Prescription
Payment
Select pharmacy



$14,644.86
Print or send this coupon to your phone
About Ninlaro
Drug Details
Ninlaro (ixazomib) is a medication designed to treat multiple myeloma, particularly in patients whose cancer has returned after previous treatments. This oral drug is part of a targeted therapy known as a proteasome inhibitor. It functions by blocking proteasomes, proteins inside cancer cells that are responsible for breaking down unneeded proteins. By inhibiting these proteasomes, Ninlaro causes a buildup of cell waste, leading to the death of cancer cells. Typically, Ninlaro is taken once weekly for three weeks in a four-week cycle, often in combination with other drugs like lenalidomide and dexamethasone. While effective, it may cause gastrointestinal issues such as nausea, diarrhea, and constipation. Always consult your healthcare provider for personalized medical advice before starting any new treatment.
Price history for Ninlaro
3 Capsules, 2.3MG
Average retail price for Ninlaro
Average SaveHealth price for Ninlaro
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Ninlaro dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 2.3MG | 3 Capsules | $14,644.86 | $4,881.62 |
| 2.3MG | 1 Capsule | $4,886.95 | $4,886.95 |
| 3MG | 1 Capsule | $4,886.95 | $4,886.95 |
| 3MG | 3 Capsules | $14,644.86 | $4,881.62 |
| 4MG | 1 Capsule | $4,886.95 | $4,886.95 |
| 4MG | 3 Capsules | $14,644.86 | $4,881.62 |
Ninlaro FAQs
NINLARO (ixazomib) is not a traditional form of chemotherapy. It is a proteasome inhibitor used in combination with other medications to treat multiple myeloma, a type of blood cancer. While it is part of cancer treatment, it works differently from conventional chemotherapy drugs.
NINLARO is used in combination with other medications to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.
NINLARO and Velcade are not the same, though they are both used in the treatment of multiple myeloma. NINLARO (ixazomib) is an oral proteasome inhibitor, while Velcade (bortezomib) is a proteasome inhibitor administered via injection. They have different active ingredients and administration methods.
NINLARO (ixazomib) is not commonly associated with weight gain. However, patients may experience other side effects, and any unexpected changes in weight should be discussed with a healthcare provider to rule out other causes or related issues.
NINLARO (ixazomib) can cause certain side effects related to the eyes. These may include blurred vision, dry eyes, and conjunctivitis. It is important for patients to report any changes in vision or eye discomfort to their healthcare provider, as these symptoms may require further evaluation or management.